Abstract: The present invention relates to compositions and methods for treating autoimmune, microbial, metabolic, neoplastic, and posttraumatic diseases mediated by inflammation in a subject. Compositions and methods including at least one importin beta-selective nuclear transport modifier (NTM) and/or at least one importin alpha-selective NTM, and/or at least one importin alpha-specific NTM, and/or at least one inhibitor of importin alpha and importin beta complex formation may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease or abrogation of inflammation.

Abstract: A method of measuring a biomechanical parameter of soft biological tissue is described. The method includes a pre-measurement process wherein an impulse applying device applies a pre-pressure to a surface of the tissue via an end portion contacting the tissue surface. While maintaining the pre-pressure, the device generates at least two impulses separated by a time interval, each impulse causing the end portion to impart to the tissue an action with certain parameters, each action inducing a response of the tissue. A value of a biomechanical parameter of the tissue is determined from each response induced. A determination is made as to whether the determined values of the biomechanical parameter are sufficiently similar to each other to indicate that the pre-pressure, the parameters of the end portion actions and the time interval are acceptable for use in a measurement process to be conducted on the surface of the tissue.

Abstract: This disclosure provides methods for treatment comprising co-administering insulin and glucagon to a subject, and co-formulations comprising insulin and glucagon.

Abstract: Provided herein are methods and compositions for determining the susceptibility of Parkinson's disease patients to optimized drug therapy (ODT) and or deep brain stimulation (DBS) therapy.

Abstract: A method for administration of citrulline for the treatment of sickle cell disease and other complications of sickle cell disease thereof.

Abstract: Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds of formula (Ia), which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

Abstract: Disclosed herein are substituted 2-azaspiro[3.3]heptane compounds of formula (I?), which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

Abstract: Systems and methods for a running controller for a lower limb device including at least a powered knee joint are provided. The method includes collecting real-time sensor information for the lower limb device and configuring the lower limb device to a first state in a finite state model for an activity mode including the running mode. The method further includes, based on the sensor information, transitioning the lower limb device from a current state to a subsequent state in the finite state model for the detected mode when a pre-defined criteria for transitioning to the subsequent state is met, and repeating the transitioning until the activity mode changes. In the system and method, the finite state model includes at least one stance state and at least one swing state, where the at least one stance state includes at least one absorption state and at least one propulsion state.

Abstract: Pyridine quinoline compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.

Abstract: The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.

Abstract: Disclosed are methods of preparing everninomicin analogs by genetic alteration of Micromonospora carbonacea. Everninomicin analogs prepared by these methods and methods of using these analogs to treat infections are also disclose.

Abstract: The present invention relates generally to shape memory polymer devices that are porous. The porosity of the device may generate advantageous neovascularization, decrease inflammation, and decrease fibrosis. The device may include a surface having a pore size of 500-750 microns and a pore spacing of 220-250 microns.

Abstract: Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

Abstract: The present disclosure is directed to antibodies binding to Aspergillus allergens and methods for use thereof.

Abstract: Provided are improved optical detection systems and methods for using same, which systems and methods comprise single channel interferometric detection systems and methods for determining a characteristic property of samples. Such interferometric detection systems and methods employ a light beam that impinges two or more discrete zones along a channel, thereby avoiding variations that can result in increases in detection limits and/or measurement errors.

Abstract: Disclosed are catheter systems and methods of using the catheter system to acquire mucosal impedance data of a patient. Also disclosed are methods of classifying or otherwise identifying esophageal conditions in a subject based on mucosal impedance data acquired using a catheter system. Unlike conventions systems that require subjective input from a physician to render a diagnosis, the systems and methods described herein can utilize the mucosal impedance measurements to generate a probability that the subject's esophagus corresponds to an esophageal condition or a set of esophageal conditions. In one embodiment, a classification model is used to generate the probability. The classification model may generate the probability based at least in part on a change in the mucosal impedance measurements between a distal location and a proximal location on the subject's esophagus.

Abstract: In spite of significant efforts to identify ?-cell-specific markers for ?-cell imaging and purification, progress has been limited. Herein is disclosed a novel biomarker of human pancreatic ?-cells, CD39L3 (also known as ectonucleoside triphosphate diphosphohydrolase-3 (NTPDase3)). Disclosed are compositions and methods for purifying and imaging ?-cell using anti-CD39L3 antibodies.